Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer
07:55pm, Tuesday, 13'th Jan 2026
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss
07:51pm, Tuesday, 13'th Jan 2026
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
10:22am, Tuesday, 13'th Jan 2026
U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Tuesday, 13'th Jan 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
GRIMES & Co WEALTH MANAGEMENT LLC Trims Position in Amgen Inc. $AMGN
06:10am, Tuesday, 13'th Jan 2026
GRIMES and Co WEALTH MANAGEMENT LLC decreased its holdings in Amgen Inc. (NASDAQ: AMGN) by 5.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Comm
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:16pm, Monday, 12'th Jan 2026
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amgen says MariTide helped trial patients maintain weight loss
07:42pm, Monday, 12'th Jan 2026
An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a second mid-stage trial in diabetes patients showed that it lowered their blood
Amgen to announce data on obesity drug MariTide at healthcare conference
06:46pm, Monday, 12'th Jan 2026
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
10:01am, Monday, 12'th Jan 2026
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips
07:40am, Sunday, 11'th Jan 2026
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
09:52am, Saturday, 10'th Jan 2026
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive
Amgen Inc. $AMGN Shares Bought by Ferguson Wellman Capital Management Inc.
04:33am, Friday, 09'th Jan 2026
Ferguson Wellman Capital Management Inc. grew its position in shares of Amgen Inc. (NASDAQ: AMGN) by 2.7% during the undefined quarter, according to the company in its most recent disclosure with the
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Thursday, 08'th Jan 2026
In the closing of the recent trading day, Amgen (AMGN) stood at $330.05, denoting a -3.39% move from the preceding trading day.
Can These Dividend Stocks Beat the Market Again in 2026?
08:37am, Thursday, 08'th Jan 2026
Building on a strong 2025, CVS Health's outlook for 2026 and beyond looks promising. Amgen is developing newer drug products that will address a recent patent cliff.
CoreCap Advisors LLC Lowers Position in Amgen Inc. $AMGN
04:55am, Thursday, 08'th Jan 2026
CoreCap Advisors LLC reduced its position in shares of Amgen Inc. (NASDAQ: AMGN) by 26.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.
